Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ABCNNYSE:EMCNYSE:FRXTSE:PLI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsEMCEMC$26.97+0.7%$0.00$22.99▼$29.13N/AN/A13.90 million shs781 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsPLIProMetic Life SciencesC$0.00C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%EMCEMC-0.24%+0.98%+15.53%+0.64%+1.51%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCNVIVO CannabisN/AN/AN/AN/AN/AN/AN/AN/AEMCEMC0.4784 of 5 stars0.02.01.70.00.01.70.7FRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO Cannabis 0.00N/AN/AN/AEMCEMC 0.00N/AN/AN/AFRXForest Road Acquisition 0.00N/AN/AN/APLIProMetic Life Sciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/AEMCEMCN/AN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/APLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/AEMCEMCN/A$2.0513.15∞N/AN/AN/AN/AN/AFRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/AEMCEMC$0.461.71%N/A22.44%N/AFRXForest Road AcquisitionN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCNVIVO CannabisN/AN/AN/AEMCEMCN/AN/AN/AFRXForest Road AcquisitionN/A0.370.37PLIProMetic Life Sciences37.474.063.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/AEMCEMC79.86%FRXForest Road AcquisitionN/APLIProMetic Life SciencesN/AInsider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/AEMCEMC0.40%FRXForest Road AcquisitionN/APLIProMetic Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableEMCEMCN/AN/AN/ANot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionableABCN, PLI, EMC, and FRX HeadlinesRecent News About These CompaniesNew PLI Treatise Helps Practitioners Navigate the Complexities of Trade Secret LawOctober 3, 2024 | ipwatchdog.comRethinking rare diseases: treat the whole patientAugust 29, 2024 | pharmaphorum.comPanetta Institute for Public PolicyMarch 31, 2024 | scu.edu2024 Breakthrough Prizes in Life SciencesOctober 11, 2023 | the-scientist.comTMC Life Sciences Bhd (TMCN)July 24, 2023 | investing.comLife Sciences Learning CommunityJune 13, 2023 | slu.eduChicago Life Sciences SummitApril 21, 2023 | bisnow.comCollege of Liberal Arts & SciencesApril 10, 2023 | alfred.eduLabviva nets $20M Series A to ease life science procurement processMarch 27, 2023 | endpts.comTrends that will shape the life sciences industry in 2023 and beyondFebruary 24, 2023 | hindustantimes.comPharma sector gets first tranche of payment under under PLI schemeFebruary 24, 2023 | moneycontrol.comArithmos appoints Maurizio Giraudo as Managing Director of the new Life Sciences Business Consulting UnitFebruary 21, 2023 | finance.yahoo.comWEF, Telangana joins hands to start thematic centre on healthcare and life sciencesJanuary 18, 2023 | health.economictimes.indiatimes.comWorking on PLI schemes for more sectors: Piyush GoyalSeptember 24, 2022 | retail.economictimes.indiatimes.comTSX:CVE (CENOVUS ENERGY INC.)July 31, 2021 | fool.caTop HeadlinesView All HeadlinesTariff Exemptions Set the Stage for a Taiwan Semiconductor RallyBy Gabriel Osorio-Mazilli | April 17, 2025View Tariff Exemptions Set the Stage for a Taiwan Semiconductor RallyApplied Digital: AI Data Center Hype or Real Value?By Jea Yu | April 21, 2025View Applied Digital: AI Data Center Hype or Real Value?O’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsBy Thomas Hughes | April 27, 2025View O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors3M Stock: 4 Compelling Reasons to Buy, 1 Big Reason to PassBy Jea Yu | April 29, 2025View 3M Stock: 4 Compelling Reasons to Buy, 1 Big Reason to PassQualcomm: Analyst Opinions Split, But Upside Potential RemainsBy Sam Quirke | May 6, 2025View Qualcomm: Analyst Opinions Split, But Upside Potential RemainsABCN, PLI, EMC, and FRX Company DescriptionsVIVO Cannabis CVE:ABCNC$1.32 +0.07 (+5.60%) As of 08/3/2018ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.EMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.ProMetic Life Sciences TSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
